Synergistic interaction of selected marine animal anticancer drugs against human diffuse large cell lymphoma

Anti-Cancer Drugs

Volumn 9, Issue 2, 1998, Pages 149-156

  Mohammad, Ramzi M ^a   Pettit, George R ^b   Almatchy, Victor P ^a   Wall, Nathan ^a   Varterasian, Mary ^a   Al Katib, Ayad ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Auristatin PE; B cell; Bryostatin 1; Dolastatin 10; SCID mice; Vincristine; Xenografts

Indexed keywords

ANTINEOPLASTIC AGENT; AURISTATIN PE; BRYOSTATIN 1; DOLASTATIN 10; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL COUNT; CELL GROWTH; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; MITOSIS; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT;

EID: 0031888974     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199802000-00006     Document Type: Article

References (22)

1. Armitage JO, Berg AR, Purtilo DT. Adult non-Hodgkin's. In: Bick RL, Bennett JM, Brynes RK, et al., eds. Hematology: clinical and laboratory practice. St Louis, MO: CV Mosby 1993; 2: 875-93.
2. Miller TP, Dana BW, Weick JK, et al. Southwest Oncology Group clinical trials for intermediate and high grade non-Hodgkin's lymphoma. Semin Hentatol 1988; 25: 17-22.
3. Fisher RI, Gaynor E, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-6.
4. Pettit GR, Herald CL, Doubek DL, Herald DL, Arnold E, Clardy J. Isolation and structure of Bryostatin 1. J Am Chem Soc 1982; 104: 6846-8.
5. Hornung RL, Pearson JW, Beckwith M, Longo DL. Preclinical evaluation of bryostatin 1 as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res 1992; 52: 101-7.
6. Pettit GR. The bryostatins. In: Herz W, Kirby GW, Steglich W, Tamm CH, eds. Progress in the chemistry of organic natural products. New York: Springer-Verlag 1991: 154-95.
7. Al-Katib A, Mohammad RM, Khan K, Dan M, Pettit GR, Sensenbrenner LL. Bryostatin 1 induced modulation of the acute lymphoblastic leukemia cell line REH. J Immunother 1993; 14: 33-42.
8. Al-Katib A, Mohammad RM, Dan M, et al. Bryostatin 1 induced hairy cell features on chronic lymphocytic leukemia cells in vitro. Exp Hematol 1993; 21: 61-5.
9. Mohammad RM, Al-Katib A, Pettit GR, Sensenbrenner LL. Differential effects of bryostatin 1 on human non-Hodgkin's B-lymphoma cell lines. Leuk Res 1993; 17: 1-8.
10. Mohammad RM, Al-Katib A, Pettit GR, Sensenbrenner LL. Successful treatment of human Waldenstrom's macroglobulinemia with combination biological and chemotherapy agents. Cancer Res 1994; 54: 165-8.
11. Pettit GR, Kamano Y, Herald CL, et al. The isolation and structure of a remarkable marine animal antineoplastic constituent: Dolastatin 10. J Am Chem Soc 1987; 109: 6883-94.
12. Pettit GR. The Dolastatins. In Herz W, Kirby GW, Moore RE, Steglich W, Tamm Ch, eds. Progress in the chemistry of organic natural products. New York: Springer 1997: 2-63.
13. Bai R, Roach MC, Jayaram SK, et al. Differential effects of active isomers, segments, and analogs of dolastatin 10 on ligand interactions with tubulin. Correlation with cytotoxicity. Biochem Pharmacol 1993; 45: 1503-15.
14. Pettit GR, Srirangam JK, Barkoczy J, et al. Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications. Anti-Cancer Drug Des 1995; 10: 529-44.
15. Mohammad RM, Diwakaran H, Maki A, et al. Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma. Leuk Res 1995; 19: 667-73.
16. Maki A, Diwakaran H, Redman B, et al. The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma. Anti-Cancer Drugs 1995; 6: 392-7.
17. Corbett TH, Valeriote FA, Polin L, et al. Discovery of solid tumor active agents using a soft-agar-colony-formation disk-diffusion assay. In: Valeriote FA, Corbett TH, Baker LH, eds. Cytotoxic anticancer drugs: models and concepts for drug discovery and development. Boston, MA: Kluwer 1992: 35.
18. DeVita V Jr, Canellos G, Chabner B, Shein F, Hubbard S, Young R. Advanced diffuse histiocytic lymphoma, a potentially curable disease: results with combination chemotherapy. Lancet 1975; i: 248-50.
19. Gordon LI, Harrington D, Andersen J, et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992; 327: 1342-9.
20. Kobayashi M, Natsume T, Tamaoki S, et al. Antitumor activity of TZT-1027, a novel dolastatin 10 derivative. Jap J Cancer Res 1997; 88: 316-27.
21. Bai R, Pettit GR, Hamel E. Dolstatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol 1990; 39: 1941-9.
22. Luduena RF, Roach MC, Prasad V, Pettit GR. Interaction of Dolastatin 10 with bovine brain tubulin. Biochem Pharmacol 1992 43: 539-43.